Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis A Eichenauer

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
Expert Review of Hematology|June 20, 2023
Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatmentDennis A Eichenauer, Sylvia Hartmann
Leukemia & Lymphoma|January 2, 2025
Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectivesDennis A Eichenauer, Peter Borchmann
Innere Medizin (Heidelberg, Germany)|October 19, 2023
[Diagnostics and treatment of hemophagocytic lymphohistiocytosis]Dennis A Eichenauer, Boris Böll
Cancers|July 14, 2023
Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?Dennis A Eichenauer, Michael Fuchs
Blood|March 5, 2011
One size for all in Hodgkin lymphoma?Dennis A Eichenauer, Andreas Engert
Hematology. American Society of Hematology. Education Program|December 10, 2017
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique managementDennis A Eichenauer, Andreas Engert
Acta Haematologica|May 30, 2015
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?Dennis A Eichenauer, Andreas Engert
Innere Medizin (Heidelberg, Germany)|September 13, 2023
[Treatment of hemophagocytic lymphohistiocytosis in patients in the intensive care unit]Dennis A Eichenauer, Paul La Rosée
Leukemia & Lymphoma|December 16, 2011
Adolescents with Hodgkin lymphoma: old children or young adults?Dennis A Eichenauer, Peter Borchmann, Andreas Engert
Expert Opinion on Pharmacotherapy|April 23, 2014
Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectivesDennis A Eichenauer, Boris Böll, Volker Diehl
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
Expert Review of Hematology|June 20, 2023
Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatmentDennis A Eichenauer, Sylvia Hartmann
Leukemia & Lymphoma|January 2, 2025
Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectivesDennis A Eichenauer, Peter Borchmann
Innere Medizin (Heidelberg, Germany)|October 19, 2023
[Diagnostics and treatment of hemophagocytic lymphohistiocytosis]Dennis A Eichenauer, Boris Böll
Cancers|July 14, 2023
Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?Dennis A Eichenauer, Michael Fuchs
Blood|March 5, 2011
One size for all in Hodgkin lymphoma?Dennis A Eichenauer, Andreas Engert
Hematology. American Society of Hematology. Education Program|December 10, 2017
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique managementDennis A Eichenauer, Andreas Engert
Acta Haematologica|May 30, 2015
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?Dennis A Eichenauer, Andreas Engert
Innere Medizin (Heidelberg, Germany)|September 13, 2023
[Treatment of hemophagocytic lymphohistiocytosis in patients in the intensive care unit]Dennis A Eichenauer, Paul La Rosée
Leukemia & Lymphoma|December 16, 2011
Adolescents with Hodgkin lymphoma: old children or young adults?Dennis A Eichenauer, Peter Borchmann, Andreas Engert
Expert Opinion on Pharmacotherapy|April 23, 2014
Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectivesDennis A Eichenauer, Boris Böll, Volker Diehl
Pageof 13